

108

Design, Synthesis, and Biological Evaluation of Novel Anti-VZV Agents

Marco Derudas^{1,*}, Christopher McGuigan¹, Robert Snoeck², Graciella Andrei², Erik De Clercq², Jan Balzarini²

¹ Welsh School of Pharmacy, Cardiff University, Cardiff, UK;

² Rega Institute for Medical Research, Leuven, Belgium

Varicella zoster virus (VZV) currently affects about 95% of the population of industrialised countries and there are approximately 500,000 cases of shingles reported annually in the U.S. (NIAID, 2007). Previously we reported the potent and selective anti-VZV activity of unusual fluorescent bicyclic nucleosides analogues (BCNAs) characterised by a fused bicyclic pyrimidine ring (McGuigan *et al.*, 1999). Initial studies found that the long alkyl chain on the aglycone to be essential for activity. The optimisation of the lead compound resulted in a series of 6-alkylphenyl derivatives, which showed a greatly improved antiviral activity (McGuigan *et al.*, 2000). In particular Cf1743 (Fig. 1) emerged as the most potent compound reported against VZV to date (EC₅₀ of 0.1 nM) which is ca. 10,000 times more potent than the current treatment acyclovir.

In the present work, we report a series of novel modified derivatives of Cf1743 designed to enhance potency and bioavailability. The synthesis and biological evaluation of these compounds will be presented.

References

- McGuigan, C., Yarnold, J., Jones, G., Velazquez, S., Barucki, H., Brancale, A., Andrei, G., Snoeck, R., De Clercq, E., Balzarini, J., 1999. *J. Med. Chem.* 42, 4479–4484.
- McGuigan, C., Barucki, H., Blewett, S., Carangio, A., Erichsen, J.T., Andrei, G., Snoeck, R., De Clercq, E., Balzarini, J., 2000. *J. Med. Chem.* 43, 4993–4997.
- National Institute of Allergy and Infectious Disease, www3.niaid.nih.gov.




Fig. 1. Structure of Cf1743.

109

Synthesis and Properties of Chiral Open-Ring Acyclic Nucleoside Bisphosphonates

Petra Doláková*, Martin Dračinský, Antonín Holý

Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nám. 2, 166 10 Prague, Czech Republic

New generation of acyclic nucleoside phosphonates (ANP, 1) is based on replacement of purine heterocycle by 2,4-diamino-6-hydroxy- or 2-amino-4,6-dihydroxypyrimidine (Fig. 1). The antiviral activity of so-called “open-ring” ANPs (2) is enantiospecific and parallel to that of the corresponding ANPs with the complete purine ring.

In the SAR studies, we prepared open-ring derivatives containing at the positions 4- and 6- of the pyrimidine moiety two identical or different chiral phosphonate-bearing substituents (3). Bisphosphonates (3) were prepared by alkylation of 4,6-dihydroxy-2-methylthiopyrimidine with appropriate synthon and subsequent ammonolysis of 2-methylthio group to amino group. In contrast to alkylation of 2-amino-4,6-dihydroxypyrimidine, which gives mixture of *O*- and *N*-alkylated regioisomers, alkylation of 2-methylthio derivative affords exclusively *O*-alkylated product.

Details of synthesis, biological activities and formation of metal ion complexes will be discussed.

Acknowledgements: This work is a part of the research project Z4 055 0506. It was supported by the “Centre for New Antivirals and Antineoplastics” (Ministry of Education, Youth and Sports of the Czech Republic, 1M0508), by the Programme of Targeted Projects of Academy of Sciences of the Czech Republic (1QS400550501) and by Gilead Sciences, Inc. (Foster City, CA, U.S.A.). We gratefully acknowledge the financial support of the European Commission (René Descartes Prize-2001 Grant no. HPAW-2002-100096).




Fig. 1.

doi:10.1016/j.antiviral.2007.01.117